SARS-CoV-2 viral load and shedding kinetics

Nature Reviews Microbiology, Journal Year: 2022, Volume and Issue: unknown

Published: Dec. 2, 2022

Language: Английский

---

A multinational Delphi consensus to end the COVID-19 public health threat

Nature, Journal Year: 2022, Volume and Issue: 611(7935), P. 332 - 345

Published: Nov. 3, 2022

Abstract Despite notable scientific and medical advances, broader political, socioeconomic behavioural factors continue to undercut the response COVID-19 pandemic 1,2 . Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel 386 academic, health, non-governmental organization, government other experts in from 112 countries territories recommend specific actions end persistent global threat public health. The developed set 41 consensus statements 57 recommendations governments, health systems, industry key stakeholders across six domains: communication; systems; vaccination; prevention; treatment care; inequities. In wake nearly three years fragmented national responses, it is instructive note that highest-ranked call for adoption whole-of-society whole-of-government approaches 1 , while maintaining proven prevention measures using vaccines-plus approach 2 employs range financial support complement vaccination. Other with at least 99% combined agreement advise governments improve communication, rebuild trust engage communities 3 management responses. findings which have been further endorsed by 184 organizations globally, include points unanimous agreement, well >5% disagreement, provide social policy address inadequacies help bring an end.

Language: Английский

---

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

The Lancet Respiratory Medicine, Journal Year: 2022, Volume and Issue: 10(8), P. 739 - 748

Published: May 20, 2022

Language: Английский

---

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1

Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(3), P. 315 - 321.e3

Published: Feb. 19, 2024

COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report administration an monovalent mRNA vaccine booster (XBB.1.5 MV) previously uninfected individuals boosted serum virus-neutralizing antibodies significantly not only (27.0-fold increase) EG.5.1 (27.6-fold also key emerging such as HV.1, HK.3, JD.1.1, JN.1 (13.3- 27.4-fold increase). Individuals infected by Omicron subvariant had highest overall neutralizing titers (ID

Language: Английский

---

SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic

Immunity, Journal Year: 2022, Volume and Issue: 55(10), P. 1764 - 1778

Published: Aug. 18, 2022

Language: Английский

---

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

Science Translational Medicine, Journal Year: 2022, Volume and Issue: 14(662)

Published: Sept. 14, 2022

Emergence of SARS-CoV-2 variants concern (VOCs), including the highly transmissible Omicron and Delta strains, has posed constant challenges to current COVID-19 vaccines that principally target viral spike protein (S). Here, we report a nucleoside-modified messenger RNA (mRNA) vaccine expresses more conserved nucleoprotein (mRNA-N) show mRNA-N vaccination alone can induce modest control SARS-CoV-2. Critically, combining with clinically proven S-expressing mRNA (mRNA-S+N) induced robust protection against both variants. In hamster models VOC challenge, demonstrated that, compared mRNA-S alone, combination mRNA-S+N not only in lungs but also provided enhanced upper respiratory tract. vivo CD8

Language: Английский

---

Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination

Science Translational Medicine, Journal Year: 2023, Volume and Issue: 15(709)

Published: Aug. 16, 2023

An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally invasive and lung-targeted delivery a host of pulmonary diseases. Development mRNA has been limited by poor transfection efficiency risk vehicle-induced pathology. Here, we report an polymer-based vehicle therapeutic mRNAs to the lung. We optimized biodegradable poly(amine- co -ester) (PACE) polyplexes using end-group modifications polyethylene glycol. These achieved high throughout lung, particularly in epithelial antigen-presenting cells. applied this technology develop mucosal vaccine severe acute respiratory syndrome coronavirus 2 found that intranasal vaccination with spike protein–encoding induced potent cellular humoral adaptive immunity protected susceptible mice from lethal viral challenge. Together, these results demonstrate translational potential PACE lungs.

Language: Английский

---

Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report

npj Vaccines, Journal Year: 2023, Volume and Issue: 8(1)

Published: April 12, 2023

On November 7th and 8th, 2022, The National Institute of Allergy Infectious Diseases (NIAID), part the Institutes Health (NIH), Coalition for Epidemic Preparedness Innovation (CEPI), Bill & Melinda Gates Foundation (BMGF), Biomedical Advanced Research Development Authority (BARDA), Wellcome Trust hosted a virtual workshop entitled "Mucosal Vaccines SARS-CoV-2: Scientific Gaps Opportunities." During workshop, researchers vaccine developers from around world discussed potential mucosal vaccines to block SARS-CoV-2 transmission reviewed status research. Here, we summarize key challenges opportunities in basic, translational, clinical research that were highlighted during meeting. We also provide recommendations advance field accelerate development SARS-CoV-2.

Language: Английский

---

Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization

Nature, Journal Year: 2023, Volume and Issue: 624(7992), P. 630 - 638

Published: Dec. 13, 2023

Language: Английский

---

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters

Nature Microbiology, Journal Year: 2023, Volume and Issue: 8(5), P. 860 - 874

Published: April 3, 2023

Abstract Vaccines play a critical role in combating the COVID-19 pandemic. Future control of pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and ability to reduce virus transmission. Here we compare immune responses preclinical mRNA vaccine BNT162b2, adenovirus-vectored spike Ad2-spike live-attenuated candidate sCPD9 Syrian hamsters, using both homogeneous heterologous vaccination regimens. Comparative was assessed by employing readouts from titrations single-cell RNA sequencing. Our results show that elicited most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation pre-plasmablasts, strong systemic mucosal humoral responses, recall memory T cells lung after challenge SARS-CoV-2. Overall, our demonstrate offer advantages over currently available vaccines.

Language: Английский

---